Literature DB >> 20944999

Antigenic extracts of Leishmania braziliensis and Leishmania amazonensis associated with saponin partially protects BALB/c mice against Leishmania chagasi infection by suppressing IL-10 and IL-4 production.

Rafaella F Q Grenfell1, Eduardo A Marques-da-Silva, Miriam C Souza-Testasicca, Eduardo A F Coelho, Ana Paula Fernandes, Luís Carlos C Afonso, Simone A Rezende.   

Abstract

This study evaluated two vaccine candidates for their effectiveness in protecting BALB/c mice against Leishmania chagasi infection. These immunogenic preparations were composed of Leishmania amazonensis or Leishmania braziliensis antigenic extracts in association with saponin adjuvant. Mice were given three subcutaneous doses of one of these vaccine candidates weekly for three weeks and four weeks later challenged with promastigotes of L. chagasi by intravenous injection. We observed that both vaccine candidates induced a significant reduction in the parasite load of the liver, while the L. amazonensis antigenic extract also stimulated a reduction in spleen parasite load. This protection was associated with a suppression of both interleukin (IL)-10 and IL-4 cytokines by spleen cells in response to L. chagasi antigen. No change was detected in the production of IFN-γ. Our data show that these immunogenic preparations reduce the type 2 immune response leading to the control of parasite replication.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20944999     DOI: 10.1590/s0074-02762010000600015

Source DB:  PubMed          Journal:  Mem Inst Oswaldo Cruz        ISSN: 0074-0276            Impact factor:   2.743


  7 in total

Review 1.  Proteoliposomes in nanobiotechnology.

Authors:  P Ciancaglini; A M S Simão; M Bolean; J L Millán; C F Rigos; J S Yoneda; M C Colhone; R G Stabeli
Journal:  Biophys Rev       Date:  2012-01-18

2.  Leishmania braziliensis and Leishmania amazonensis amastigote extracts differ in their enhancement effect on Leishmania infection when injected intradermally.

Authors:  Cintia F de Araújo; Virgínia M G Silva; Andre Cronemberger-Andrade; Luciana S Aragão-França; Viviane C J Rocha; Priscila S L Santos; Lain Pontes-de-Carvalho
Journal:  BMC Res Notes       Date:  2014-02-01

3.  Cross-protective effect of a combined L5 plus L3 Leishmania major ribosomal protein based vaccine combined with a Th1 adjuvant in murine cutaneous and visceral leishmaniasis.

Authors:  Laura Ramirez; Laura Corvo; Mariana C Duarte; Miguel A Chávez-Fumagalli; Diogo G Valadares; Diego M Santos; Camila I de Oliveira; Marta R Escutia; Carlos Alonso; Pedro Bonay; Carlos A P Tavares; Eduardo A F Coelho; Manuel Soto
Journal:  Parasit Vectors       Date:  2014-01-02       Impact factor: 3.876

4.  Synthesis, anti-leishmanial and molecular docking study of bis-indole derivatives.

Authors:  Muhammad Taha; Imad Uddin; Mohammed Gollapalli; Noor Barak Almandil; Fazal Rahim; Rai Khalid Farooq; Muhammad Nawaz; Mohamed Ibrahim; Mohammed A Alqahtani; Yasser A Bamarouf; Manikandan Selvaraj
Journal:  BMC Chem       Date:  2019-08-06

5.  IL-4 contributes to failure, and colludes with IL-10 to exacerbate Leishmania donovani infection following administration of a subcutaneous leishmanial antigen vaccine.

Authors:  Sudipta Bhowmick; Rajesh Ravindran; Nahid Ali
Journal:  BMC Microbiol       Date:  2014-01-15       Impact factor: 3.605

6.  Efficient one-pot synthesis, molecular docking and in silico ADME prediction of bis-(4-hydroxycoumarin-3-yl) methane derivatives as antileishmanial agents.

Authors:  Zahid Zaheer; Firoz A Kalam Khan; Jaiprakash N Sangshetti; Rajendra H Patil
Journal:  EXCLI J       Date:  2015-08-10       Impact factor: 4.068

7.  Immunoprophylactic Potential of a Cocktail of Three Low Molecular Weight Antigens of Leishmania donovani along with Various Adjuvants Against Experimental Visceral leishmaniasis.

Authors:  Harpreet Kaur; Ankita Thakur; Sukhbir Kaur
Journal:  Iran J Parasitol       Date:  2018 Jan-Mar       Impact factor: 1.012

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.